Late Risk for Recurrence with Estrogen Receptor–Positive Breast Cancer

During extended follow-up, recurrence risk was significantly higher with ER-positive versus ER-negative disease.

Large datasets with long-term follow-up offer insights into the natural history of disease. Such information has always been important, but it is becoming more actionable, particularly in hormone receptor–positive breast cancer, for which consideration is given to longer durations of adjuvant endocrine therapy and molecular assays are being developed to help identify patients most appropriate for long-term treatment. The International Breast Cancer Study Group (IBCSG) previously conducted a series of pivotal trials evaluating chemotherapy and endocrine therapy in patients with early-stage breast cancer (EBC).

Now, the investigators report on long-term follow-up of IBCSG clinical trials I to V, which accrued EBC patients from 1978 to 1985. Tr…

Reviewing Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)